Abstract
Background: RECOVER (NCT00474058), a double-blind, placebo-controlled trial in patients with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control, demonstrated significant improvements with rotigotine in early-morning motor function (Unified Parkinson's Disease Rating Scale [UPDRS] III), and nocturnal sleep disturbances (modified Parkinson's Disease Sleep Scale [PDSS-2]), and improvements in nonmotor symptoms (NMS; Non-Motor Symptom Scale [NMSS]). Methods: Post hoc analyses investigated the correlation between motor symptom and NMS severity in PD by evaluating associations between UPDRS III and both NMSS and PDSS-2 scores. Categories were defined for UPDRS III, NMSS, and PDSS-2 total scores; analyses were conducted for the full analysis set (n = 267). Results: There was a trend toward increasing PDSS-2 and NMSS total and domain scores with increasing UPDRS III category at baseline and end of maintenance (EoM). Pearson correlation coefficients between UPDRS III and both NMSS and PDSS-2 total and domain scores were r = 0.12-0.44 (r2 = 0.01-0.19) at baseline, r = 0.05-0.38 (r2 = 0.00-0.14) at EoM, and r = -0.02-0.36 (r2 = 0.00-0.13) for change from baseline to EoM. Conclusion: There was only a small correlation between severity of early-morning motor symptoms and overall burden of NMS and nocturnal sleep disturbances in RECOVER, suggesting that motor symptoms and NMS originate, at least partly, from distinct pathophysiological pathways.
References
1.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD: The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Move Disord 2009;24:1641-1649.
2.
Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR: Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Move Disord 2007;22:1623-1629.
3.
Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson's disease. Move Disord 2001;16:507-510.
4.
Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
5.
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Move Disord 2011;26:399-406.
6.
Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
7.
Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ: Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-931.
8.
Global Parkinson's Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson's disease: results from an international survey. Move Disord 2002;17:60-67.
9.
Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
10.
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA: Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
11.
Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
12.
Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, MacMahon DG, Peto V, Playfer JR: Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Move Disord 2003;18:1139-1145.
13.
Ahlskog JE: Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Move Disord 2005;20:271-282.
14.
Benarroch EE: Central neurotransmitters and neuromodulators in cardiovascular regulation; in Mathias CJ, Bannister R (eds): Autonomic Failure, ed 4. Oxford, Oxford University Press, 1999, pp 37-44.
15.
Arnulf I, Ferraye M, Fraix V, Benabid AL, Chabardes S, Goetz L, Pollak P, Debû B: Sleep induced by stimulation in the human pedunculopontine nucleus area. Ann Neurol 2010;67:546-549.
16.
Swick TJ: Parkinson's disease and sleep/wake disturbances. Parkinsons Dis 2012;2012:205471.
17.
Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
18.
Chaudhuri KR: The dopaminergic basis of sleep dysfunction and nonmotor symptoms of Parkinson's disease: evidence from functional imaging. Exp Neurol 2009;216:247-248.
19.
Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W: Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-978.
20.
Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Move Disord 2007;22:2398-2404.
21.
Jankovic J, Watts RL, Martin W, Boroojerdi B: Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-682.
22.
LeWitt PA, Lyons KE, Pahwa R: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-1267.
23.
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-520.
24.
Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276.
25.
Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Move Disord 2011;26:90-99.
26.
Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F, Cooperative Multicentric Group: Unified Parkinson's Disease Rating Scale characteristics and structure. Move Disord 1994;9:76-83.
27.
Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, Prakash R, Esselink RA, Falup-Pecurariu C, Gallardo M, Mir P, Naidu Y, Nicoletti A, Sethi K, Tsuboi Y, van Hilten JJ, Visser M, Zappia M, Chaudhuri KR: International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009;73:1584-1591.
28.
Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH: The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Move Disord 2007;22:1901-1911.
29.
Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, Hülsmann J, Martinez-Martin P, Chaudhuri KR: Parkinson's disease sleep scale-validation of the revised version PDSS-2. Move Disord 2011;26:644-652.
30.
Storch A, Schneider CB, Wolz M, Sturwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G: Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800-809.
31.
Antonini A, Albin RL: Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology 2013;80:784-785.
32.
Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, Ramat S, Ceravolo MG, Meco G, Cicarelli G, Pederzoli M, Manfredi M, Ceravolo R, Mucchiut M, Volpe G, Abbruzzese G, Bottacchi E, Bartolomei L, Ciacci G, Cannas A, Randisi MG, Petrone A, Baratti M, Toni V, Cossu G, Del Dotto P, Bentivoglio AR, Abrignani M, Scala R, Pennisi F, Quatrale R, Gaglio RM, Nicoletti A, Perini M, Avarello T, Pisani A, Scaglioni A, Martinelli PE, Iemolo F, Ferigo L, Simone P, Soliveri P, Troianiello B, Consoli D, Mauro A, Lopiano L, Nastasi G, Colosimo C: The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012;259:2621-2631.
33.
van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ: Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:846-850.
34.
Tandberg E, Larsen JP, Karlsen K: A community-based study of sleep disorders in patients with Parkinson's disease. Move Disord 1998;13:895-899.
35.
Partinen M: Sleep disorder related to Parkinson's disease. J Neurol 1997;244:S3-S6.
36.
Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982;5:183-194.
37.
van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RA: Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Trans 1993;5:235-244.
38.
Lees AJ, Blackburn NA, Campbell VL: The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-519.
39.
Friedman JH, Chou KL: Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2004;10:S27-S35.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
